Published in Am J Pathol on August 01, 1988
Human cytomegalovirus activates inflammatory cytokine responses via CD14 and Toll-like receptor 2. J Virol (2003) 3.97
Human cytomegalovirus productively infects primary differentiated macrophages. J Virol (1991) 3.16
Human herpesviruses: a consideration of the latent state. Microbiol Rev (1989) 3.15
Induction of endogenous human cytomegalovirus gene expression after differentiation of monocytes from healthy carriers. J Virol (1994) 2.68
The enhancer domain of the human cytomegalovirus major immediate-early promoter determines cell type-specific expression in transgenic mice. J Virol (1996) 2.37
The promoter-regulatory region of the major immediate-early gene of human cytomegalovirus responds to T-lymphocyte stimulation and contains functional cyclic AMP-response elements. J Virol (1989) 2.32
Unrestricted replication of human cytomegalovirus in hydrocortisone-treated macrophages. J Virol (1991) 2.07
Human cytomegalovirus induces monocyte differentiation and migration as a strategy for dissemination and persistence. J Virol (2004) 1.66
Reactivation of latent human cytomegalovirus in CD14(+) monocytes is differentiation dependent. J Virol (2001) 1.65
Interferon-gamma and tumor necrosis factor-alpha specifically induce formation of cytomegalovirus-permissive monocyte-derived macrophages that are refractory to the antiviral activity of these cytokines. J Clin Invest (1997) 1.62
Human cytomegalovirus persistently infects aortic endothelial cells. J Virol (1998) 1.55
Growth kinetics of human cytomegalovirus are altered in monocyte-derived macrophages. J Virol (1995) 1.52
Human cytomegalovirus (HCMV) infection of endothelial cells promotes naive monocyte extravasation and transfer of productive virus to enhance hematogenous dissemination of HCMV. J Virol (2006) 1.44
Steady-state plasma membrane expression of human cytomegalovirus gB is determined by the phosphorylation state of Ser900. J Virol (1998) 1.29
Human cytomegalovirus elicits a coordinated cellular antiviral response via envelope glycoprotein B. J Virol (2004) 1.27
Demonstration of cytomegalovirus nucleic acids in the coronary arteries of transplanted hearts. Am J Pathol (1992) 1.08
Human cytomegalovirus tropism for endothelial cells: not all endothelial cells are created equal. J Virol (2006) 1.00
Acquisition of cytomegalovirus infection: an update. Clin Microbiol Rev (1989) 0.91
Human cytomegalovirus inhibits cytokine-induced macrophage differentiation. J Virol (2004) 0.90
Human cytomegalovirus infection. Thorax (1989) 0.88
Dendritic cell biology in human cytomegalovirus infection and the clinical consequences for host immunity and pathology. Virulence (2012) 0.84
Cytomegalovirus latency promotes cardiac lymphoid neogenesis and accelerated allograft rejection in CMV naïve recipients. Am J Transplant (2011) 0.83
Human Cytomegalovirus Induces an Atypical Activation of Akt To Stimulate the Survival of Short-Lived Monocytes. J Virol (2016) 0.76
Labeling deoxyribonucleic acid to high specific activity in vitro by nick translation with DNA polymerase I. J Mol Biol (1977) 205.11
Temporal patterns of human cytomegalovirus transcription: mapping the viral RNAs synthesized at immediate early, early, and late times after infection. J Virol (1982) 6.20
Multiple spliced and unspliced transcripts from human cytomegalovirus immediate-early region 2 and evidence for a common initiation site within immediate-early region 1. J Virol (1985) 5.09
Cytomegalovirus infects human lymphocytes and monocytes: virus expression is restricted to immediate-early gene products. Proc Natl Acad Sci U S A (1984) 4.56
Human cytomegalovirus DNA: restriction enzyme cleavage maps and map locations for immediate-early, early, and late RNAs. Virology (1981) 4.12
Detection of human cytomegalovirus in peripheral blood lymphocytes in a natural infection. Science (1985) 3.69
Cloning of the complete human cytomegalovirus genome in cosmids. Gene (1982) 3.55
Cytomegalovirus disease in renal allograft recipients: a prospective study of the clinical features, risk factors and impact on renal transplantation. Medicine (Baltimore) (1980) 3.42
Predominant immediate-early transcripts of human cytomegalovirus AD 169. J Virol (1984) 3.15
Pathogenesis of of cytomegalovirus infection. I. Activation of virus from bone marrow-derived lymphocytes by in vitro allogenic reaction. J Exp Med (1975) 3.13
The transplanted kidney as a source of cytomegalovirus infection. N Engl J Med (1975) 3.09
Primary structure and transcription of the genes coding for the two virion phosphoproteins pp65 and pp71 of human cytomegalovirus. J Virol (1987) 2.60
Cytomegalovirus infections following renal transplantation. Rev Infect Dis (1982) 2.22
Trisodium phosphonoformate, a new antiviral compound. Science (1978) 2.13
Localization of cytomegalovirus proteins and genome during fulminant central nervous system infection in an AIDS patient. J Neuropathol Exp Neurol (1986) 1.94
Association of renal allograft rejection with virus infections. Am J Med (1974) 1.83
Physical mapping of human cytomegalovirus genes: identification of DNA sequences coding for a virion phosphoprotein of 71 kDa and a viral 65-kDa polypeptide. Virology (1984) 1.81
Immunosuppression reactivates and disseminates latent murine cytomegalovirus. J Gen Virol (1977) 1.79
Clinical manifestations of renal allograft derived primary cytomegalovirus infection. Am J Dis Child (1977) 1.60
Cytomegalovirus infection in transplant patients. Prog Med Virol (1982) 1.57
Replication of human cytomegalovirus in human peripheral blood T cells. J Virol (1986) 1.45
Infectious disease syndromes attributable to cytomegalovirus and their significance among renal transplant recipients. Transplantation (1977) 1.40
Enhancement of mouse cytomegalovirus infection during host-versus-graft reaction. Science (1975) 1.40
Cytomegalovirus: Clinical virological correlations in renal transplant recipients. Ann Surg (1974) 1.34
Expression of HLA-DR on T lymphocytes following renal transplantation, and association with graft-rejection episodes and cytomegalovirus infection. Transplantation (1984) 1.32
Multicenter seroepidemiologic study of the impact of cytomegalovirus infection on renal transplantation. Transplantation (1985) 1.29
Reduction of postperfusion cytomegalovirus-infections following the use of leukocyte depleted blood. Transfusion (1977) 1.27
The role of pretransplant immunity in protection from cytomegalovirus disease following renal transplantation. Transplantation (1985) 1.26
Composition of interstitial cellular infiltrate identified by monoclonal antibodies in renal biopsies of rejecting human renal allografts. Transplantation (1983) 1.19
Infectious diseases in hospitalized renal transplant recipients: a prospective study of a complex and evolving problem. Medicine (Baltimore) (1982) 1.16
An analysis of cytomegalovirus infection and HLA antigen matching on the outcome of renal transplantation. Ann Surg (1978) 1.15
Cytomegalovirus infection: a quantitative prospective study of three hundred twenty consecutive renal transplants. Surgery (1981) 1.08
Morphometric analysis of cellular infiltration assessed by monoclonal antibody labeling in sequential human renal allograft biopsies. Transplantation (1986) 1.01
Transmission of latent cytomegalovirus in a murine kidney tissue transplantation model. Transplantation (1985) 0.95
Viral infections in renal transplant donors and their recipients: a prospective study. Surgery (1977) 0.94
Primary and secondary cytomegalovirus infection. Arch Intern Med (1977) 0.92
Cytomegalovirus glomerulopathy: a controversial lesion. Kidney Int (1986) 0.91
High incidence of virus isolation from donor and recipient tissues associated with renal transplantation. Nature (1978) 0.91
Search for latent cytomegalovirus in renal allografts. Infect Immun (1978) 0.89
Comments on CMV infections in renal transplant patients. Yale J Biol Med (1976) 0.87
The source of murine cytomegalovirus in mice receiving kidney allografts. J Infect Dis (1985) 0.86
Reactivation of latent murine cytomegalovirus from kidney. Kidney Int (1985) 0.82
Outcome of renal transplantation in patients with primary cytomegalovirus infection. Transplant Proc (1979) 0.81
Generalized cytomegalic inclusion disease of the newborn. Localization of inclusions in the kidney. Arch Pathol (1968) 0.80
Passive transfer of cytomegalovirus by cardiac and renal organ transplants in a rat model. Transplantation (1986) 0.80
Cytomegalovirus replicates efficiently in human kidney mesangial cells. Proc Natl Acad Sci U S A (1988) 0.79
Clinical experiences with phosphonoformate (foscarnet) treatment of viral diseases following renal transplantation. Scand J Urol Nephrol Suppl (1985) 0.78
Identification of the cellular subpopulations infiltrating rejecting cadaver renal allografts. Preponderance of the T4 subset of T cells. Transplantation (1984) 0.78
Cytomegalovirus infection and graft survival in renal graft recipients. Arch Virol (1978) 0.77
Virus-specific CD8+ cytotoxic T-lymphocyte activity associated with control of viremia in primary human immunodeficiency virus type 1 infection. J Virol (1994) 15.93
Antiviral pressure exerted by HIV-1-specific cytotoxic T lymphocytes (CTLs) during primary infection demonstrated by rapid selection of CTL escape virus. Nat Med (1997) 12.08
Selection of genetic variants of lymphocytic choriomeningitis virus in spleens of persistently infected mice. Role in suppression of cytotoxic T lymphocyte response and viral persistence. J Exp Med (1984) 10.66
Cellular localization of human immunodeficiency virus infection within the brains of acquired immune deficiency syndrome patients. Proc Natl Acad Sci U S A (1986) 8.45
The virology and immunobiology of lymphocytic choriomeningitis virus infection. Adv Immunol (1980) 6.24
Pathogenesis of chronic disease associated with persistent lymphocytic choriomeningitis viral infection. I. Relationship of antibody production to disease in neonatally infected mice. J Exp Med (1969) 6.03
Identification of alpha-dystroglycan as a receptor for lymphocytic choriomeningitis virus and Lassa fever virus. Science (1998) 5.83
Differential regulation of antiviral T-cell immunity results in stable CD8+ but declining CD4+ T-cell memory. Nat Med (2001) 5.74
Biology of cloned cytotoxic T lymphocytes specific for lymphocytic choriomeningitis virus: clearance of virus in vivo. J Virol (1984) 5.57
Molecular mimicry and autoimmune disease. Cell (1987) 5.31
Cytomegalovirus infects human lymphocytes and monocytes: virus expression is restricted to immediate-early gene products. Proc Natl Acad Sci U S A (1984) 4.56
Genomic and biological variation among commonly used lymphocytic choriomeningitis virus strains. J Gen Virol (1983) 4.45
Promoter-specific trans activation and repression by human cytomegalovirus immediate-early proteins involves common and unique protein domains. J Virol (1990) 4.24
Cerebrospinal fluid human immunodeficiency virus type 1 RNA levels are elevated in neurocognitively impaired individuals with acquired immunodeficiency syndrome. HIV Neurobehavioral Research Center Group. Ann Neurol (1997) 4.17
Characterization of V3 sequence heterogeneity in subtype C human immunodeficiency virus type 1 isolates from Malawi: underrepresentation of X4 variants. J Virol (1999) 4.16
Cytoimmunotherapy for persistent virus infection reveals a unique clearance pattern from the central nervous system. Nature (1986) 4.01
Lymphocytic choriomeningitis: production of antibody by "tolerant" infected mice. Science (1967) 4.01
Reactivation of latent human cytomegalovirus by allogeneic stimulation of blood cells from healthy donors. Cell (1997) 3.99
Regulated expression of early and late RNAs and proteins from the human cytomegalovirus immediate-early gene region. J Virol (1989) 3.98
Virus-induced immunosuppression: immune system-mediated destruction of virus-infected dendritic cells results in generalized immune suppression. J Virol (1995) 3.90
Detection of human cytomegalovirus in peripheral blood lymphocytes in a natural infection. Science (1985) 3.69
Amino acid homology between the encephalitogenic site of myelin basic protein and virus: mechanism for autoimmunity. Science (1985) 3.68
BEACHES: an observational system for assessing children's eating and physical activity behaviors and associated events. J Appl Behav Anal (1991) 3.61
Seven-day recall and other physical activity self-reports in children and adolescents. Med Sci Sports Exerc (1993) 3.57
Immunosuppression and resultant viral persistence by specific viral targeting of dendritic cells. J Exp Med (2000) 3.50
Widespread presence of histologically occult cytomegalovirus. Hum Pathol (1984) 3.45
CD4-deficient mice have reduced levels of memory cytotoxic T lymphocytes after immunization and show diminished resistance to subsequent virus challenge. J Virol (1996) 3.39
Dendritic injury is a pathological substrate for human immunodeficiency virus-related cognitive disorders. HNRC Group. The HIV Neurobehavioral Research Center. Ann Neurol (1997) 3.38
Monoclonal antibodies to lymphocytic choriomeningitis and pichinde viruses: generation, characterization, and cross-reactivity with other arenaviruses. Virology (1981) 3.26
Virus-lymphocyte interactions. IV. Molecular characterization of LCMV Armstrong (CTL+) small genomic segment and that of its variant, Clone 13 (CTL-). Virology (1988) 3.22
Human cytomegalovirus US3 impairs transport and maturation of major histocompatibility complex class I heavy chains. Proc Natl Acad Sci U S A (1996) 3.17
Human cytomegalovirus productively infects primary differentiated macrophages. J Virol (1991) 3.16
Predominant immediate-early transcripts of human cytomegalovirus AD 169. J Virol (1984) 3.15
Pathogenesis of of cytomegalovirus infection. I. Activation of virus from bone marrow-derived lymphocytes by in vitro allogenic reaction. J Exp Med (1975) 3.13
Long-term infection and transformation of dermal microvascular endothelial cells by human herpesvirus 8. J Virol (1999) 3.02
The human cytomegalovirus chemokine receptor US28 mediates vascular smooth muscle cell migration. Cell (1999) 2.97
Fine mapping of an immunodominant domain in the transmembrane glycoprotein of human immunodeficiency virus. J Virol (1987) 2.97
Molecular definition of a major cytotoxic T-lymphocyte epitope in the glycoprotein of lymphocytic choriomeningitis virus. J Virol (1988) 2.82
Molecular analyses of a five-amino-acid cytotoxic T-lymphocyte (CTL) epitope: an immunodominant region which induces nonreciprocal CTL cross-reactivity. J Virol (1989) 2.79
Neurologic disease induced in transgenic mice by cerebral overexpression of interleukin 6. Proc Natl Acad Sci U S A (1993) 2.79
Analyses of the cytotoxic T lymphocyte responses to glycoprotein and nucleoprotein components of lymphocytic choriomeningitis virus. Virology (1988) 2.76
NP and L proteins of lymphocytic choriomeningitis virus (LCMV) are sufficient for efficient transcription and replication of LCMV genomic RNA analogs. J Virol (2000) 2.74
Correlates of physical activity at home in Mexican-American and Anglo-American preschool children. Health Psychol (1993) 2.74
Organ-specific selection of viral variants during chronic infection. J Exp Med (1988) 2.71
Viral cross talk: intracellular inactivation of the hepatitis B virus during an unrelated viral infection of the liver. Proc Natl Acad Sci U S A (1996) 2.68
An essential role for type 1 interferon-gamma in terminating persistent viral infection. Virology (1995) 2.60
How virus induces a rapid or slow onset insulin-dependent diabetes mellitus in a transgenic model. Immunity (1994) 2.56
The antibody response of mice to murine leukemia virus in spontaneous infection: absence of classical immunologic tolerance (AKR mice-complement-fixing antibodies-lymphocytic choriomeningitis virus-immunofluorescence-glomerular deposits of antigen-antibody complexes). Proc Natl Acad Sci U S A (1972) 2.54
Molecular characterization of the genomic S RNA segment from lymphocytic choriomeningitis virus. Virology (1987) 2.53
Viral persistence in neurons explained by lack of major histocompatibility class I expression. Science (1991) 2.51
Empiric antimicrobial therapy of domestically acquired acute diarrhea in urban adults. Arch Intern Med (1990) 2.45
Histocompatibility-linked genetic control of disease susceptibility. Murine lymphocytic choriomeningitis virus infection. J Exp Med (1973) 2.39
The enhancer domain of the human cytomegalovirus major immediate-early promoter determines cell type-specific expression in transgenic mice. J Virol (1996) 2.37
Lysis of RNA tumor viruses by human serum: direct antibody-independent triggering of the classical complement pathway. J Exp Med (1976) 2.34
Replication and persistence of measles virus in defined subpopulations of human leukocytes. J Virol (1975) 2.30
The primary structure of the lymphocytic choriomeningitis virus L gene encodes a putative RNA polymerase. Virology (1989) 2.25
Virus neutralization and virus-induced immune complex disease. Virus-antibody union resulting in immunoprotection or immunologic injury--two sides of the same coin. Prog Med Virol (1975) 2.23
CD40L-deficient mice show deficits in antiviral immunity and have an impaired memory CD8+ CTL response. J Exp Med (1996) 2.21
Surface markers on human B and T lymphocytes. VIII. Association between complement and Epstein-Barr virus receptors on human lymphoid cells. Scand J Immunol (1976) 2.18
The effect of induced chronic viral infections on the immunologic diseases of New Zealand mice. J Exp Med (1970) 2.16
Vaccination and protection from a lethal viral infection: identification, incorporation, and use of a cytotoxic T lymphocyte glycoprotein epitope. Virology (1990) 2.12
Molecular mimicry in virus infection: crossreaction of measles virus phosphoprotein or of herpes simplex virus protein with human intermediate filaments. Proc Natl Acad Sci U S A (1983) 2.12
Immunohistochemical study of allergic encephalomyelitis. Am J Pathol (1968) 2.10
Immunologic injury in measles virus infection. II. Suppression of immune injury through antigenic modulation. J Exp Med (1975) 2.09
Multiple isoforms of CD46 (membrane cofactor protein) serve as receptors for measles virus. Proc Natl Acad Sci U S A (1994) 2.08
Cytomegalovirus US2 destroys two components of the MHC class II pathway, preventing recognition by CD4+ T cells. Nat Med (1999) 2.08
Pathogenesis of the slow disease of the central nervous system associated with WM 1504 E virus. I. Relationship of strain susceptibility and replication to disease. Am J Pathol (1977) 2.08
Blood-brain barrier tight junction disruption in human immunodeficiency virus-1 encephalitis. Am J Pathol (1999) 2.07
Immunologic injury of cultured cells infected with measles virus. I. role of IfG antibody and the alternative complement pathway. J Exp Med (1975) 2.06
Transcriptional regulation of the human cytomegalovirus major immediate-early gene is associated with induction of DNase I-hypersensitive sites. Mol Cell Biol (1986) 2.05
Molecularly engineered vaccine which expresses an immunodominant T-cell epitope induces cytotoxic T lymphocytes that confer protection from lethal virus infection. J Virol (1989) 2.05
Molecular analysis of the interaction of LCMV with its cellular receptor [alpha]-dystroglycan. J Cell Biol (2001) 2.03
Pathogenesis of murine cytomegalovirus infection: the macrophage as a permissive cell for cytomegalovirus infection, replication and latency. J Gen Virol (1979) 2.01
Tissue injury in lymphocytic choriomeningitis viral infection: virus-induced immunologically specific release of a cytotoxic factor from immune lymphoid cells. Virology (1970) 2.00
Neurocognitive impairment is an independent risk factor for death in HIV infection. San Diego HIV Neurobehavioral Research Center Group. Arch Neurol (1997) 2.00
Protein structure of lymphocytic choriomeningitis virus: evidence for a cell-associated precursor of the virion glycopeptides. Virology (1979) 2.00
Virus-lymphocyte interaction: T cells of the helper subset are infected with lymphocytic choriomeningitis virus during persistent infection in vivo. J Virol (1987) 1.99
Human immunodeficiency virus infection of bone marrow endothelium reduces induction of stromal hematopoietic growth factors. Blood (1996) 1.98
Interactions between viruses and lymphocytes. I. In vivo replication of lymphocytic choriomeningitis virus in mononuclear cells during both chronic and acute viral infections. J Immunol (1978) 1.95
HIV-1 infection in a man homozygous for CCR5 delta 32. Lancet (1997) 1.95
Molecular mimicry: frequency of reactivity of monoclonal antiviral antibodies with normal tissues. J Virol (1986) 1.95
Localization of cytomegalovirus proteins and genome during fulminant central nervous system infection in an AIDS patient. J Neuropathol Exp Neurol (1986) 1.94
Mechanism of lymphocytic choriomeningitis virus entry into cells. Virology (1994) 1.93
Viruses disrupt functions of human lymphocytes. Effects of measles virus and influenza virus on lymphocyte-mediated killing and antibody production. J Exp Med (1984) 1.92
Human serum lyses RNA tumour viruses. Nature (1975) 1.92
The human cytomegalovirus IE86 protein can block cell cycle progression after inducing transition into the S phase of permissive cells. J Virol (2000) 1.92
Do pathogens accelerate atherosclerosis? J Nutr (2001) 1.91
Diagnosis of AIDS by using a 12-amino acid peptide representing an immunodominant epitope of the human immunodeficiency virus. J Infect Dis (1987) 1.91
Optimal lymphocytic choriomeningitis virus sequences restricted by H-2Db major histocompatibility complex class I molecules and presented to cytotoxic T lymphocytes. J Virol (1995) 1.90
Serial magnetic resonance imaging of experimental atherosclerosis detects lesion fine structure, progression and complications in vivo. Nat Med (1995) 1.90
Antibody-induced redistribution of measles virus antigens on the cell surface. J Immunol (1974) 1.89